AT533515T - Formulations comprising antisense nucleotides specific for connexins - Google Patents

Formulations comprising antisense nucleotides specific for connexins

Info

Publication number
AT533515T
AT533515T AT05016736T AT05016736T AT533515T AT 533515 T AT533515 T AT 533515T AT 05016736 T AT05016736 T AT 05016736T AT 05016736 T AT05016736 T AT 05016736T AT 533515 T AT533515 T AT 533515T
Authority
AT
Austria
Prior art keywords
connexins
formulations
antisense nucleotides
nucleotides specific
specific
Prior art date
Application number
AT05016736T
Other languages
German (de)
Inventor
David Dr Becker
Colin R Dr Green
Original Assignee
Coda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ33392899 priority Critical
Priority to NZ50019099 priority
Application filed by Coda Therapeutics Inc filed Critical Coda Therapeutics Inc
Publication of AT533515T publication Critical patent/AT533515T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
AT05016736T 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides specific for connexins AT533515T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ33392899 1999-01-27
NZ50019099 1999-10-07

Publications (1)

Publication Number Publication Date
AT533515T true AT533515T (en) 2011-12-15

Family

ID=26652011

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05016736T AT533515T (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides specific for connexins
AT00901236T AT300959T (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides specific for connexins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00901236T AT300959T (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides specific for connexins

Country Status (13)

Country Link
US (11) US7098190B1 (en)
EP (3) EP2314321B1 (en)
JP (4) JP4994533B2 (en)
AT (2) AT533515T (en)
AU (1) AU776512B2 (en)
CA (2) CA2361251C (en)
CY (2) CY1112557T1 (en)
DE (1) DE60021700T2 (en)
DK (3) DK1621212T3 (en)
ES (3) ES2245638T3 (en)
NZ (1) NZ513154A (en)
PT (3) PT1146908E (en)
WO (1) WO2000044409A1 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0418601B2 (en) * 1982-11-16 1992-03-27 Kawasaki Heavy Ind Ltd
AT533515T (en) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulations comprising antisense nucleotides specific for connexins
EP1197553A1 (en) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense nucleic acid against alphaV integrin
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
CA2547780A1 (en) 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
BRPI0519737A2 (en) 2004-12-21 2009-01-27 Musc Found For Res Dev compositions and methods for promoting wound healing and tissue regeneraÇço
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
EP2510939A1 (en) 2005-02-03 2012-10-17 Coda Therapeutics Limited Anti-connexin peptide mimetics and therapeutic uses thereof
JPWO2007055224A1 (en) * 2005-11-08 2009-04-30 関西ティー・エル・オー株式会社 Therapeutic agent for a corneal disease
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッドQuark Pharmaceuticals,Inc. New siRNA and methods of use thereof
EP2091557A2 (en) * 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
AU2014204482B2 (en) * 2006-12-11 2016-07-07 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
WO2008073479A2 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
DK2166845T3 (en) * 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2245061A2 (en) 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CA2709153A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
AU2008343755A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
US20110243964A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
EP2238250B1 (en) * 2007-12-21 2017-07-19 CoDa Therapeutics, Inc. Use of anti-connexin 43 polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
AU2008343756A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2710380A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
AU2008343754A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
EP2237796A2 (en) * 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
WO2009085272A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
RU2604489C2 (en) 2008-10-03 2016-12-10 КьюРНА,Инк.,US Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
JP6091752B2 (en) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Treatment of native erythropoietin by suppressing the antisense transcript (epo) related diseases for Epo
US8669941B2 (en) * 2009-01-05 2014-03-11 Nuance Communications, Inc. Method and apparatus for text entry
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
CA2755409C (en) 2009-03-16 2019-04-30 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CN102549159B (en) 2009-03-17 2016-08-10 库尔纳公司 By suppressing natural antisense transcript for the δ-like 1 homolog (DLK1) treating a disease associated DLK1
JP5883782B2 (en) 2009-05-06 2016-03-15 クルナ・インコーポレーテッド Treatment of lipid transport metabolic gene associated disease by suppressing the natural antisense transcript on lipid transport metabolism genes
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment related tristetraprolina (TTP) diseases by inhibiting natural antisense transcript for TTP
ES2618572T3 (en) 2009-05-08 2017-06-21 Curna, Inc. Treatment related to the family of dystrophin diseases by inhibiting a natural antisense transcript for the family of dmd
CA2762369A1 (en) 2009-05-18 2010-11-25 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (en) 2009-05-22 2017-09-26 库尔纳公司 By inhibiting transcription factor for e3 (tfe3) natural antisense transcript treating TFE3 protein and insulin receptor substrate 2 (irs2) related diseases
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment related Paraoxonase1 (PON1) diseases by inhibiting natural antisense transcript to PON1
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing natural antisense transcript Down's syndrome gene therapy Down's syndrome gene-related diseases
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN102625841A (en) 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2480669T3 (en) 2009-09-25 2018-02-12 Curna Inc Treatment of filaggrin (flg) related diseases by modulating flg expression and activity
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment related transcription factor peptidase membrane, site 1 (mbtps1) by inhibiting the natural antisense transcript to mbtps1 gene diseases
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc Treatment of hepatocytvækstfaktor- (HGF) related diseases by inhibition of the natural antisense transcript against HGF
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
CN102782134B (en) 2009-12-29 2017-11-24 库尔纳公司 By inhibiting NRF 1 (nrf1) natural antisense transcripts treating related diseases NRF1
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 63 is by inhibiting tumor protein (p63) of a natural antisense transcript treating p63 associated diseases
CN102791862B (en) 2009-12-31 2017-04-05 库尔纳公司 By inhibiting insulin receptor substrate 2 (irs2) and transcription factor e3 (tfe3) natural antisense transcripts treating related diseases IRS2
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc Treatment of interferon regulatory factor 8- (irf8) related diseases by inhibition of the natural antisense transcript against irf8
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
EP2553098B1 (en) 2010-04-02 2017-10-11 CuRNA, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228A (en) 2010-05-03 2018-05-04 库尔纳公司 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 Curna Inc Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP6023705B2 (en) 2010-06-23 2016-11-09 カッパーアールエヌエー,インコーポレイテッド Treatment of sodium channel, voltage-dependent, SCNA related diseases by inhibition of the natural antisense transcripts for α-subunit (SCNA)
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
RU2624048C2 (en) 2010-10-06 2017-06-30 Курна, Инк. Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 By inhibiting α-L- iduronic acid enzyme (IDUA) natural antisense transcripts treating related diseases IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
CA2838588A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2013122778A1 (en) 2012-02-15 2013-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
AU2013225716B2 (en) 2012-03-01 2017-10-12 Firststring Research, Inc. Topical gels containing alpha connexin C-terminal (ACT) peptides
EP2825648B1 (en) 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013148736A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
SG11201507211YA (en) * 2013-03-11 2015-10-29 Univ North Carolina Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
CA2932753A1 (en) * 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
EP3110455A4 (en) * 2014-02-25 2017-10-11 CoDa Therapeutics, Inc. Treatment of resistant lesions
WO2015191795A1 (en) * 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
AU1846297A (en) * 1996-01-31 1997-08-22 Regents Of The University Of California, The Method for inhibiting tumor cell growth
WO1997032982A1 (en) * 1996-03-07 1997-09-12 Eisai Co., Ltd. Human adhesion molecule occludin
DE69736862T2 (en) * 1996-07-17 2007-05-31 Medtronic, Inc., Minneapolis Delivery system for delivering genetic material to cardiac tissue
EP0950060A4 (en) * 1996-12-02 2000-07-05 Dyad Pharmaceutical Corp Antisense inhibition of human adhesion molecules
CA2313348A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
AT533515T (en) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulations comprising antisense nucleotides specific for connexins
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression

Also Published As

Publication number Publication date
DK1621212T3 (en) 2012-03-05
DE60021700T2 (en) 2006-06-01
EP1621212A1 (en) 2006-02-01
AT300959T (en) 2005-08-15
ES2377749T3 (en) 2012-03-30
PT1621212E (en) 2012-02-20
JP5736397B2 (en) 2015-06-17
US7879811B2 (en) 2011-02-01
JP2002535377A (en) 2002-10-22
DE60021700D1 (en) 2005-09-08
EP2314321B1 (en) 2014-06-04
US20080249041A1 (en) 2008-10-09
US20070072819A1 (en) 2007-03-29
US20130079388A1 (en) 2013-03-28
CA2361251A1 (en) 2000-08-03
NZ513154A (en) 2004-01-30
AU2119300A (en) 2000-08-18
JP2013135677A (en) 2013-07-11
US20070078103A1 (en) 2007-04-05
US20070037765A1 (en) 2007-02-15
DK2314321T3 (en) 2014-09-08
ES2498745T3 (en) 2014-09-25
EP1621212B1 (en) 2011-11-16
JP4994533B2 (en) 2012-08-08
PT1146908E (en) 2005-10-31
US7902164B2 (en) 2011-03-08
US20110065770A1 (en) 2011-03-17
CY1115521T1 (en) 2017-01-04
WO2000044409A1 (en) 2000-08-03
US20070060538A1 (en) 2007-03-15
US7098190B1 (en) 2006-08-29
US7615540B2 (en) 2009-11-10
US20080221051A1 (en) 2008-09-11
US20070072820A1 (en) 2007-03-29
US20070066555A1 (en) 2007-03-22
US9193754B2 (en) 2015-11-24
PT2314321E (en) 2014-09-26
EP2314321A1 (en) 2011-04-27
CA2361251C (en) 2011-03-08
AU776512B2 (en) 2004-09-09
US7919474B2 (en) 2011-04-05
JP2012041342A (en) 2012-03-01
JP2013136594A (en) 2013-07-11
CY1112557T1 (en) 2016-02-10
CA2730386A1 (en) 2000-08-03
JP5705890B2 (en) 2015-04-22
US8314074B2 (en) 2012-11-20
ES2245638T3 (en) 2006-01-16
EP1146908A1 (en) 2001-10-24
CA2730386C (en) 2015-08-11
DK1146908T3 (en) 2005-10-10
EP1146908B1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
DE60137419D1 (en) Adjusting means for tissue
DE60039888D1 (en) s
DE60010900D1 (en) Reinforcement for structures
NO20025835L (en) immunostimulatory oligodeoxynucleotides
DE60044458D1 (en) location
DE60111805D1 (en) ink composition
DE69818869D1 (en) Means for Thermozyklier devices for PCR
AT315688T (en) Shaped block for retaining wall
AT432993T (en) Tar rna-binding peptide
DE60138454D1 (en) metering
DE60109260D1 (en) printing system
DE60126935D1 (en) holder
DE60004920D1 (en) Vibrationally fluidly
DE60039184D1 (en) Tolerance genes for environmental stress
DE50113985D1 (en) holder
NO991328D0 (en) Three component chimeric antisense oligonucleotides
ATA63699A (en) Armrest for sitzmöbel
DE60136951D1 (en) Microneedle element holder for schlagapplikator
DE60137247D1 (en) Intracorporeal communication for hörhilfegerate
DE60042826D1 (en) Anode-electrode for plasmatron-structure
DE60329220D1 (en) Antisense design
DE69922794D1 (en) Synchronisierungspräambelstruktur optimized for OFDM system
DE60143521D1 (en) Inverted shaped paneel
AT245142T (en) No-synthase inhibitors
DE69936703D1 (en) Herzratenvaribilität as inkikator for physical carrying capacity